CGD gene therapy (Somatix/Baxter)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameCGD gene therapy (Somatix/Baxter)
Drug Alias NameCGD therapy (Somatix)chronic granulomatous disease therapy (Somatix)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Peripheral blood stem cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsImmune System DiseasesGenetic Diseases, Inborn
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSomatix Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSomatix IncBaxter Healthcare Corp
Active IndicationsN/A
Inactive IndicationsImmune System DiseasesGenetic Diseases, Inborn

Other Information

ATC CodeN/A
Related LinksN/A